US008735372B2

(12) **United States Patent**
Du et al.

(10) **Patent No.: US 8,735,372 B2**
(45) **Date of Patent: May 27, 2014**

(54) **NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS**

(71) Applicant: **Gilead Pharmassett LLC**, Foster City, CA (US)

(72) Inventors: **Jinfa Du**, Redwood City, CA (US); **Dhanapalan Nagarathnam**, Bethany, CT (US); **Michael Joseph Sofia**, Doylestown, PA (US); **Peiyuan Wang**, Totowa, NJ (US)

(73) Assignee: **Gilead Pharmasset LLC**, Foster City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/057,675**

(22) Filed: **Oct. 18, 2013**

(65) **Prior Publication Data**

US 2014/0045783 A1 Feb. 13, 2014

Related U.S. Application Data

(63) Continuation of application No. 13/609,614, filed on Sep. 11, 2012, now Pat. No. 8,580,765, which is a continuation of application No. 13/099,671, filed on May 3, 2011, now Pat. No. 8,334,270, which is a continuation of application No. 12/053,015, filed on Mar. 21, 2008, now Pat. No. 7,964,580.

(60) Provisional application No. 60/982,309, filed on Oct. 24, 2007, provisional application No. 60/909,315, filed on Mar. 30, 2007.

(51) **Int. Cl.**
A01N 43/04 (2006.01)
A61K 31/70 (2006.01)

(52) **U.S. Cl.**
USPC **514/51**; 514/43; 514/49; 514/50

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,798,209	A	3/1974	Witkowski et al.
3,852,267	A	12/1974	Meyer, Jr. et al.
RE29,835	E	11/1978	Witkowski et al.
4,814,477	A	3/1989	Wijnberg et al.
4,957,924	A	9/1990	Beauchamp
5,026,687	A	6/1991	Yarchoan et al.
5,118,820	A	6/1992	Hertel
5,149,794	A	9/1992	Yatvin et al.
5,157,027	A	10/1992	Biller et al.
5,192,549	A	3/1993	Barenolz et al.
5,194,654	A	3/1993	Hostetler et al.
5,223,263	A	6/1993	Hostetler et al.
5,256,641	A	10/1993	Yatvin et al.
5,256,798	A	10/1993	Chou et al.
5,372,808	A	12/1994	Blatt et al.
5,376,380	A	12/1994	Kikuchi et al.
5,405,598	A	4/1995	Schinazi et al.
5,411,947	A	5/1995	Hostetler et al.
5,420,266	A	5/1995	Britton et al.
5,426,183	A	6/1995	Kjell
5,453,499	A	9/1995	Chou et al.
5,462,724	A	10/1995	Schinazi et al.
5,463,092	A	10/1995	Hostetler et al.
5,496,546	A	3/1996	Wang et al.
5,538,865	A	7/1996	Reyes et al.
5,543,389	A	8/1996	Yatvin et al.
5,543,390	A	8/1996	Yatvin et al.
5,543,391	A	8/1996	Yatvin et al.
5,554,728	A	9/1996	Basava et al.
5,610,054	A	3/1997	Draper
5,633,358	A	5/1997	Gruetzke et al.
5,633,388	A	5/1997	Diana et al.
5,676,942	A	10/1997	Testa et al.
5,703,058	A	12/1997	Schinazi et al.
5,711,944	A	1/1998	Gilbert et al.
5,725,859	A	3/1998	Omer
5,738,845	A	4/1998	Imakawa
5,738,846	A	4/1998	Greenwald et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	101108870	A	1/2008
DE	199 14 474	A1	10/1999

(Continued)

OTHER PUBLICATIONS

Gudmundsson, Kristjan S., et al., "Phosphoramidate Protides of Carbocyclic 2',3'-Dideoxy-2',3'-Didehydro-7-Deazaadenosine with Potent Activity Against HIV and HBV," Nucleosides, Nucleotides & Nucleic Acids (2004) 23(12): 1929-1937.

(Continued)

Primary Examiner — Patrick Lewis
(74) *Attorney, Agent, or Firm* — Fitzpatrick, Cella, Harper & Scinto

(57) **ABSTRACT**

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:

I



Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

2 Claims, No Drawings